||In the 6- and 8-week MDD studies, proportion of patients with metabolic shifts was similar to placebo. Monitor weight at baseline and frequently thereafter. The mean weight changes reported in this study were VRAYLAR 1-2 mg/day + ADT (n=273) = +1.98 lb VRAYLAR 2 -4.5 mg/day + ADT (n=273) = +1.98 lb placebo + ADT (n=266) = 0 lbs. ![]() ![]() In the 8-week MDD study, 2.5% of people taking VRAYLAR + ADT had a weight increase of ≥7% vs 2% of those taking placebo. The mean weight changes reported in these studies were VRAYLAR 1.5 mg/day + ADT (n=502) = +1.54 lb VRAYLAR 3 mg/day + ADT (n=503) = +1.54 lb placebo + ADT (n=503) = +0.44 lb. In two 6-week MDD studies, 2% of people taking VRAYLAR + ADT had a weight increase of ≥7% vs 1% of those taking placebo + ADT. In the 6-week studies, 4% of the patients who received VRAYLAR discontinued treatment due to an adverse reaction, compared with 2% of placebo-treated patients in these trials. ‡The most common adverse reactions observed in the two 6-week MDD studies (≥5% and at least twice the rate of placebo) were akathisia, nausea, and insomnia.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |